

<b>REF</b>	510-1	6x3mL	<b>EXP</b>	2026-07-22	<b>LOT</b>	30A620C	更新日期:	2024-07
								1 / 2

		批号: 30A620C					
项目\仪器\试剂方法	单位	均值 \ CV		Lab \ 点数			
<b>(AFP)甲胎蛋白</b>							
Roche cobas E601/602	ng/mL	4.51	10%	10	255		
Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)							
Beckman UniCel Dxl 600/800	ng/mL	4.34	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Siemens ADVIA Centaur XP/XPT	ng/mL	3.2	12%	<5	<100		
Dedicated \ Chemiluminescence enzyme immunoassay (CLEIA)							
Roche Modular E170	ng/mL	4.2	12%	<5	<100		
Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)							
Abbott ARCHITECT i series	ng/mL	3.83	2.2%	<5	<100		
Abbott \ Chemiluminescence Immunoassay (CLIA)							
<b>(CA 125)糖类抗原 125</b>							
Roche cobas E601/602	IU/mL	26.2	3.3%	10	252		
Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)							
Siemens ADVIA Centaur XP/XPT	IU/mL	23.7	12%	<5	<100		
Dedicated \ Chemiluminescence enzyme immunoassay (CLEIA)							
Roche Modular E170	IU/mL	24.5	12%	<5	<100		
Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)							
Abbott ARCHITECT i series	IU/mL	35	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
DiaSorin Liaison /XL	IU/mL	29	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Abbott ARCHITECT i series	IU/mL	34.1	0.4%	<5	<100		
Abbott \ Chemiluminescence Immunoassay (CLIA)							
<b>(CA 15-3)糖类抗原 15-3</b>							
Roche cobas E601/602	IU/mL	17.3	4.3%	10	255		
Roche \ Chemiluminescence enzyme immunoassay (CLEIA)							
Siemens ADVIA Centaur XP/XPT	IU/mL	16.5	12%	<5	<100		
Dedicated \ Chemiluminescence enzyme immunoassay (CLEIA)							
Roche Modular E170	IU/mL	16.2	12%	<5	<100		
Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)							
Abbott ARCHITECT i series	IU/mL	18	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
DiaSorin Liaison /XL	IU/mL	17.1	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Abbott ARCHITECT i series	IU/mL	18.8	0.4%	<5	<100		
Abbott \ Chemiluminescence Immunoassay (CLIA)							
<b>(CA 19-9)糖类抗原 19-9</b>							
Roche cobas E601/602	IU/mL	14.1	4.4%	10	251		
Roche \ Chemiluminescence enzyme immunoassay (CLEIA)							
DiaSorin Liaison /XL	IU/mL	24.1	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Siemens ADVIA Centaur XP/XPT	IU/mL	24.7	12%	<5	<100		
Dedicated \ Chemiluminescence enzyme immunoassay (CLEIA)							
Roche Modular E170	IU/mL	15.6	12%	<5	<100		
Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)							
Abbott ARCHITECT i series	IU/mL	37	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Abbott ARCHITECT i series	IU/mL	39.4	5.1%	<5	<100		
Abbott \ Chemiluminescence Immunoassay (CLIA)							
<b>(CA 72-4)糖类抗原 72-4</b>							
Roche Modular E170	IU/mL	3.3	12%	<5	<100		
Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)							
<b>(CEA)癌胚抗原</b>							
Roche cobas E601/602	ng/mL	2.25	5.6%	10	236		
Roche \ Chemiluminescence enzyme immunoassay (CLEIA)							
Siemens ADVIA Centaur XP/XPT	ng/mL	1.7	12%	<5	<100		
Dedicated \ Chemiluminescence enzyme immunoassay (CLEIA)							
Beckman UniCel Dxl 600/800	ng/mL	2.22	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Roche Modular E170	ng/mL	2.3	12%	<5	<100		
Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)							
Abbott ARCHITECT i series	ng/mL	3.3	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Abbott ARCHITECT i series	ng/mL	2.78	0%	<5	<100		
Abbott \ Chemiluminescence Immunoassay (CLIA)							
<b>(Cyfra 21-1)细胞角蛋白19片段</b>							
Roche Modular E170	ng/mL	2	12%	<5	<100		
Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)							
<b>(Ferritin)铁蛋白</b>							
Beckman Access	ng/mL	34.2	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Siemens ADVIA Centaur XP/XPT	ng/mL	39	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							
Abbott ARCHITECT i series	ng/mL	52	12%	<5	<100		
Dedicated \ Chemiluminescence Immunoassay (CLIA)							

<b>REF</b>	510-1	6x3mL	<b>EXP</b>	2026-07-22	<b>LOT</b>	30A620C	更新日期:	2024-07
								2 / 2

		批号: 30A620C			
项目\仪器\试剂方法	单位	均值 \ CV		Lab \ 点数	
Roche Modular E170 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	62.2	12%	<5	<100
<b>(F-PSA)游离前列腺特异性抗原</b>					
Abbott ARCHITECT i series Abbott \ Chemiluminescence Immunoassay (CLIA )	ng/mL	1.1	11.7%	<5	<100
Siemens ADVIA Centaur XP/XPT Siemens \ Chemiluminescence Immunoassay (CLIA )	ng/mL	1.08	12%	<5	<100
Beckman Access Beckman Coulter \ Chemiluminescence Immunoassay (CLIA )	ng/mL	1.5	12%	<5	<100
Roche Modular E170 Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	0.96	12%	<5	<100
<b>(NSE)神经元特异性烯醇化酶</b>					
Roche cobas E601/602 Roche \ Chemiluminescence enzyme immunoassay (CLEIA)	ng/mL	0.804	11.6%	10	254
<b>(PSA)前列腺特异性抗原</b>					
Abbott ARCHITECT i series Abbott \ Chemiluminescence Immunoassay (CLIA )	ng/mL	2.95	13%	<5	<100
Roche cobas E601/602 Roche \ Chemiluminescence enzyme immunoassay (CLEIA)	ng/mL	2.3	4.1%	10	249
Roche Modular E170 Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	2.97	12%	<5	<100
Beckman Access Beckman Coulter \ Chemiluminescence Immunoassay (CLIA )	ng/mL	3.01	12%	<5	<100
Siemens ADVIA Centaur XP/XPT Siemens \ Chemiluminescence Immunoassay (CLIA )	ng/mL	2.42	12%	<5	<100
<b>(SCC)鳞状细胞癌抗原</b>					
Abbott AxSYM Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	1.5	12%	<5	<100
<b>(TPA)组织多肽抗原</b>					
DiaSorin Liaison /XL Dedicated \ Chemiluminescence Immunoassay (CLIA )	U/L	452	12%	<5	<100
<b>(TPS)组织多肽特异抗原</b>					
Siemens Immulite1000/2000 Dedicated \ Chemiluminescence Immunoassay (CLIA )	U/L	4	12%	<5	<100
<b>(β-hCG)人绒毛膜促性腺激素β亚基</b>					
Roche cobas E601/602 Roche \ Chemiluminescence enzyme immunoassay (CLEIA)	IU/mL	0.013	4.9%	10	203
Roche Modular E170 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	IU/mL	0.013	12%	<5	<100
Siemens ADVIA Centaur XP/XPT Dedicated \ Chemiluminescence Immunoassay (CLIA )	IU/mL	0.011	12%	<5	<100

注：此报告所提供的数据均基于检测相同批号质控品的若干实验室的数据汇总统计而来，仅供学习、参考之用。因所用技术、仪器和试剂的不同，或因制造商检测方法的改变，均可导致实验室实际测得的数据偏离此报告所提供的数据。根据良好实验室规范的要求，实验室须遵循相关技术规范确立自己的均值和可接受范围。